Gram Hermann
Novartis Institutes of BioMedical Research, Forum 1, CH-4002 Basel, Switzerland.
Curr Opin Chem Biol. 2016 Jun;32:1-9. doi: 10.1016/j.cbpa.2015.12.003. Epub 2015 Dec 23.
Interleukin-1beta (IL-1β) is a pro-inflammatory cytokine which is part of the first line innate response in vertebrates and is induced in injury, infection, and immunity. While temporally limited induction of IL-1β is believed to protect the organisms against traumatic or infectious insults, its aberrant expression in chronic inflammation is detrimental. Therefore, pharmacological neutralization of IL-1β in chronic inflammatory diseases is a meaningful strategy to treat inflammation and to alleviate respective clinical symptoms in man. Canakinumab is a high-affinity human monoclonal antibody designed to target human IL-1β in inflammatory diseases. Indeed, canakinumab has shown excellent efficacy in rare genetic autoinflammatory diseases or pathological conditions associated with aberrant production of IL-1β. This review focuses on the molecular and clinical mode of action and pharmaceutical development of canakinumab in (auto)inflammatory diseases.
白细胞介素-1β（IL-1β）是一种促炎细胞因子，是脊椎动物一线固有免疫反应的一部分，在损伤、感染和免疫过程中被诱导产生。虽然IL-1β的诱导在时间上受到限制被认为可保护机体免受创伤或感染性损伤，但其在慢性炎症中的异常表达是有害的。因此，在慢性炎症性疾病中对IL-1β进行药理学中和是治疗炎症及缓解人类相应临床症状的一种有意义的策略。卡那单抗是一种高亲和力的人源单克隆抗体，旨在靶向炎症性疾病中的人IL-1β。事实上，卡那单抗在罕见的遗传性自身炎症性疾病或与IL-1β异常产生相关的病理状况中已显示出卓越的疗效。本综述重点关注卡那单抗在（自身）炎症性疾病中的分子和临床作用模式以及药物研发情况。
